Kazia Therapeutics Ltd's paxalisib now the subject of multi-drug platform study at the University Hospital, Zurich
Kazia Therapeutics Ltd (ASX:KZA, NASDAQ:KZIA) welcomes the news that the multi-drug GBM AGILE study in glioblastoma has opened recruitment to the paxalisib...